PR86251

MENLO PARK, Calif., Oct. 27, 2020 /PRNewswire=KYODO JBN --

Drawbridge Health, a healthcare technology company redefining the blood draw

experience for both patients and healthcare providers, today announced a

further investment from Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo

Dainippon Pharma") as well as a new research and development collaboration

agreement.  Drawbridge Health also reported that it has secured a strategic

investment from new investor TOHO HOLDINGS CO., LTD. ("TOHO HOLDINGS"), in

addition to a follow-on investment from Kyoto University Innovation Capital

("KYOTO-iCAP"). The investments will fuel Drawbridge Health's expansion in the

Japanese market and support adoption of the company's innovative blood

collection technology, the OneDraw(RM) Blood Collection Device

(https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=3872382273&u=https%3A%2F%2Fwww.drawbridgehealth.com%2Fonedraw%2F&a=OneDraw%E2%84%A2+Blood+Collection+Device ).

Photo - https://mma.prnewswire.com/media/1318588/dbh_onedraw_kit_04.jpg 

Photo - https://mma.prnewswire.com/media/899446/Drawbridge_Logo.jpg 

The collaboration between Drawbridge Health and Sumitomo Dainippon Pharma will

focus initially on the development of a biomarker panel for lifestyle-related

diseases such as diabetes and diabetic complications. "Our research and

development collaboration with Drawbridge Health has been undertaken to address

the significant concern in Japan around lifestyle-related diseases by embracing

OneDraw as a novel, transformative innovation" said Hiroyuki Baba, Senior

Executive Officer at Sumitomo Dainippon Pharma.

Professor Nobuya Inagaki, M.D., Ph.D., Chairman of the Department of Diabetes,

Endocrinology and Nutrition at Kyoto University further highlighted the

significance of the collaboration between Drawbridge Health and Sumitomo

Dainippon Pharma. "This collaboration is forward-thinking, as it will help

advance much-needed initiatives, resources and support the expansion of

telemedicine in the Japanese medical field, particularly for lifestyle-related diseases."

"There is tremendous potential for changing the trajectory of diabetes and

lifestyle disease in Japan with the OneDraw device. We are excited to partner

with Drawbridge Health to improve the health of millions," said Mr. Atsushi

Udoh, President and Representative Director, TOHO HOLDINGS.

"Globally, 2020 has proven that healthcare systems must quickly adapt to

unexpected and ongoing challenges. Access to health information is more

important than ever, and we appreciate the commitments from Sumitomo Dainippon

Pharma and TOHO HOLDINGS as we continue our growth and vision in Japan. We also

continue to be extremely grateful for the ongoing collaboration and relationship with

Kyoto University and KYOTO-iCAP," said Lee McCracken, CEO of Drawbridge Health.

Drawbridge Health is committed to improving healthcare globally through more

accessible blood sampling, beginning with the 2019 FDA-cleared

(https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=3961682480&u=https%3A%2F%2Fwww.drawbridgehealth.com%2Ffda-510k%2F&a=FDA-cleared ) and 2020 CE-marked (https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=3133559943&u=https%3A%2F%2Fwww.drawbridgehealth.com%2Fce-mark-approval%2F&a=CE-marked ) OneDraw A1C Test System. OneDraw is a small, single use device that draws,

collects, and stabilizes a capillary blood sample from the upper arm. This

novel device is easy to use and enables blood to be drawn comfortably and

conveniently without the need to visit a lab.

About Drawbridge Health

Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a

healthcare technology company focused on reinventing the blood draw experience,

enabling comfortable convenient blood sample collection anytime and anywhere.

By integrating engineering, chemistries, and modular design, Drawbridge Health

has developed a people-friendly system for collecting and stabilizing blood

samples, opening new doors to enable access to important health information.

For more information, please visit www.drawbridgehealth.com .

Contact:

Eddy Garcia

egarcia@dbhealth.com

Learn more about the investors:

Sumitomo Dainippon Pharma (https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=776878814&u=https%3A%2F%2Fwww.ds-pharma.com%2F&a=Sumitomo+Dainippon+PharmaTOHO+HOLDINGS+CO.%2C+LTD.+ )

TOHO HOLDINGS CO., LTD. (https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=776878814&u=https%3A%2F%2Fwww.ds-pharma.com%2F&a=Sumitomo+Dainippon+PharmaTOHO+HOLDINGS+CO.%2C+LTD.+ )

KYOTO-iCAP (https://c212.net/c/link/?t=0&l=en&o=2959041-1&h=4021996195&u=https%3A%2F%2Fwww.kyoto-unicap.co.jp%2Fen%2Fcompany%2F&a=KYOTO-iCAP )

SOURCE: Drawbridge Health